The Southwest Oncology Group: Progress in Cancer Research

Seminars in Oncology

Volumn 35, Issue 5, 2008, Pages 545-552

  Coltman Jr , Charles A ^a  

^a Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE; BCG VACCINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FINASTERIDE; FLUDARABINE; FLUOROURACIL; FLUTAMIDE; FOLINIC ACID; GOSERELIN; LEUPRORELIN; LEVAMISOLE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PENTOSTATIN; PLACEBO; PREDNISONE; SELENIUM; TAMOXIFEN; UNINDEXED DRUG; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; MYELOMA; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RETINA MACULA AGE RELATED DEGENERATION; SARCOMA; STATISTICAL ANALYSIS; TRAINING; UROGENITAL TRACT CANCER;

BREAST NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MEDICAL ONCOLOGY; NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 52949093446     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.07.001     Document Type: Article

References (47)

1. Green S., Benedetti J., and Crowley J. Clinical trials in oncology: interdisciplinary statistics (2002), Chapman & Hall/CRC, London
2. Smith A., Kopecky K.J., et al. The Southwest Oncology Group specimen tracking system: a web-based tool to support correlative science in a multi-disease cooperative group setting. Clin Trials 3 (2006) 214-215
3. Rothenberg M.L., Coltman C.A., and Fu Kushima M. Summary of a joint meeting between the Southwest Oncology Group and the Japanese Clinical Trials Consortium. J Cancer Res Clin Oncol. 119 (1993) 564-567
4. Gandara D.R., Kawaguchi T., Crowley J.J., Moon J., Kawahara M., Teramukai S., et al. Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics. J Clin Oncol. 25 Suppl 18 (2007) 7500
5. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 394 (2003) 215-224
6. Klein E.A., Thompson I.M., Lippman S.M., Goodman P.J., Albanes D., Taylor P.R., et al. SELECT: The Selenium and Vitamin E Cancer Prevention Trial Rational and Design. Prostate Cancer Prostatic Dis 3 (2000) 145-151
7. Rivkin S.E., Green S., Metch B., Glucksberg H., Gad-el-Mawla N., Constanzi J.J., et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol. 7 (1989) 1229-1238
8. Rivkin S.E., Green S., Metch B., Jewell W.R., Constanzi J.J., Altman S.J., et al. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 11 (1993) 1710-1716
9. Taylor C.W., Green S., Dalton W.S., Martino S., Rector D., Ingle J.N., et al. Multicenter randomized clinical trial of goserelin versus surgical oophorectomy in premenopausal patients with receptor-positive metastatic breast cancer: an Intergroup Study. J Clin Oncol. 16 (1998) 994-999
10. Albain K., Green S., Ravdin P., Cobau C., Levine, Ingle J., et al. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen (CAFT) is superior to T alone in postmenopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group intergroup trial S8814 (INT-0100). [abstract]. Proc Am Soc Clin Oncol. (2001) A94
11. Hutchins L., Green S., Ravdin P., Lew D., Martino S., Abeloff M., et al. CMF Versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102. [abstract]. Proc Am Soc Clin Oncol. 17 (1998) A2
12. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 322 (1990) 352-358
13. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., et al. The Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 13 (1995) 2936-2943
14. Macdonald J.S., Smalley S., Benedetti J., Estes N., Haller D.G., Ajani J.A., et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of Intergroup Study INT-0116 (SWOG 9008). [abstract]. Proc Am Soc Clin Oncol. 19 (2000) A1
15. Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.M., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345 (2001) 725-730
16. Lamm D.L., Blumenstein B.A., Crawford E.D., Montie J.E., Scardino P., Grossman H.B., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 325 (1991) 1205-1209
17. Lamm D.L., Crawford E.D., Blumenstein B.A., Crissman J.D., Montie J., Gottesman J., et al. Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study. [abstract]. Proc Am Soc Clin Oncol. (1992) A627
18. Lamm D.L. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology 9 (1995) 947-952
19. Crawford E.D., Eisenberger M.A., McLeod G.D., Spaulding J.T., Benson R., Dorr F.A., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321 (1989) 419-424
20. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 349 (2003) 859-866
21. Thompson I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically-advanced prostate cancer: a randomized, clinical trial. JAMA 296 (2006) 2329-2335
22. Eisenberger M.A., Blumenstein B.A., Crawford E.D., Miller G., McLeod G.D., Loehrer P.J., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 339 (1998) 1036-1042
23. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 345 (2001) 1655-1659
24. Petrylak D.P., Tangen C.M., Hussain M.H.A., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351 (2004) 1513-1520
25. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. Classic Papers Current Comments 3 (1998) 145-157
26. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335 (1996) 1950-1955
27. National Cancer Institute. Concurrent chemoradiation for cervical cancer (1999) Press Release, February
28. Schuller D.E., Metch B., et al. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 98 (1998) 1205-1211
29. Al-Sarraf M., LeBlanc M., Gin P.G.S., Fu K., Cooper J., Vuong T., et al. Superiority of chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (pts) with locally advanced nasopharyngeal cancer (NPC): Preliminary results of intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) randomized study [abstract]. Proc Am Soc Clin Oncol. 15 (1996) A882
30. Al-Sarraf M., LeBlanc M., Gin P.G.S., Fu K., Cooper J., Vuong T., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 16 (1998) 1310-1317
31. Grever M.R., Kopecky K.J., Coltman C.A., Files J.C., Greenberg B.R., et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 30 (1988) 457-459
32. Weick J.K., Kopecky K.J., Appelbaum F.R., Head D.R., Kingsbury L.L., Balcerzak S.P., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88 (1996) 2841-2851
33. Grever M., Kopecky K., Foucar K.M., Head D., Bennett J.M., Hutchison R.E., et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 13 (1995) 974-982
34. List A.F., Kopecky K.J., Willman C., Spier C., Dorr R., Flaherty L., et al. Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: a Southwest Oncology Group (SWOG) study. [abstract]. Blood 92 (1998) A1281
35. Bunn Jr. P.A., Crowley J., Kelly K., Hazuka M.B., Beasley K., Upchurch C., et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol. 13 (1995) 1632-1641
36. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 16 (1998) 2459-2465
37. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Mainpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 19 (2001) 3210-3218
38. Ramsey S.D., Moinpour C.M., Lovalo L.C., Grevstad P.K., Presant C., Gandara O., et al. An economic analysis alongside a prospective randomized multicenter clinical trial of cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced non small cell lung cancer. Lung Cancer 29 Suppl 2 (2000) 4
39. Fabian C.J., Mansfield C.M., et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. A Southwest Oncology Group randomized study. Ann Intern Med. 120 (1994) 903-912
40. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 328 (1993) 1002-1006
41. Miller T.P., Dahlberg S., Cassady J.R., Adelstein D.J., Spier C.M., Grogan T.M., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high grade non-Hodgkin's lymphoma. N Engl J Med. 339 (1998) 21-26
42. Dana B.W., Unger J., Fisher R.I., et al. A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to Pro-MACE-MOPP (day 1-8) (SWOG 8809). [abstract]. Proc Am Soc Clin Oncol. 17 (1998) A10
43. Press O.W., LeBlanc M., Lichter A., Wasserman T.H., Miller T., Fisher R., et al. A Phase III randomized intergroup trial of subtotal lymphoid irradiation (STLO) versus doxorubicin, vinblastine, and STLI for stage IA-IIA Hodgkin's disease. [abstract]. Blood 96 (2000) 575a
44. Koops H.S., Vaglini M., Suciu S., Suclu S., Kroon B.B.R., Thompson J.F., Gohl J., et al. Prophylactic isolated limb perfusion for localized high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol. 16 (1998) 2906-2912
45. Meyskens Jr. F.L., Kopecky K.J., Taylor C.W., Noyes R.D., Tuthill R.J., Hersh E.M., et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 87 (1995) 1710-1713
46. Berenson J., Crowley J., Barlogie B., and Salmon S. Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients. [abstract]. Blood 92 (1998) A1305
47. Demetri G.D., Rankin C., Fletcher C., Benjamm R.S., Blanke C., Von Mehren M., et al. Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: Intergroup S0033 early results. [abstract 1651]. Proc Am Soc Clin Oncol. 21 (2002) 413a